GEN Exclusives

More »

GEN News Highlights

More »
Oct 7, 2009

Genzyme's Label-Expansion Efforts for ALL Therapy Receive Setback from the FDA

  • FDA has recommended that Genzyme perform an additional clinical study with its cancer medication Clolar for label expansion into previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. Clolar is currently approved for pediatric acute lymphoblasic leukemia (ALL) patients who have relapsed or have refractory disease after at least two prior regimens.

    It has orphan drug designation for AML and pediatric ALL and seven years of market exclusivity in the U.S. for the approved indication. The FDA granted six months of extended market exclusivity to Clolar under the Best Pharmaceuticals for Children Act.

    Genzyme had sought approval to expand the indication based on the findings from a single-arm trial in an adult AML population. The FDA is now asking for a randomized, placebo-controlled trial, and the company will meet with the agency to discuss the optimal path forward, including what additional or ongoing studies may satisfy regulatory requirements.

    Genzyme is currently conducting a randomized, placebo-controlled Phase III study comparing Clolar in combination with cytarabine to cytarabine alone in relapsed and refractory adult AML patients 55 years old or older. Results are expected in 2011.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »